MedTrace Logo

Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer

NCT06840704 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2026-04-02

No results posted yet for this study

Summary

This study aims to evaluate the efficacy of immunonutrition in reducing acute esophagitis after thoracic radiotherapy in lung cancer.

Conditions

Interventions

DIETARY_SUPPLEMENT

Oral immunonutrition

Oral immunonutrition (Oral Impact®, Nestlé), 250 ml per bottle, with a dosage of 2 bottles per day, starting on the day of radiotherapy and continuing for three weeks after radiotherapy.

Sponsors & Collaborators

  • Hunan Cancer Hospital

    lead OTHER

Principal Investigators

  • Huai Liu, M.D. · Hunan Cancer Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-25
Primary Completion
2026-06-30
Completion
2026-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06840704 on ClinicalTrials.gov